Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on January 12, 2 ...